Journal Info

Journal Info

副标题

For Authors

For Authors

副标题

For Reviewers

For Reviewers

副标题

2024, Vol. 28 ›› Issue (23): 3736-3742

Osteoprotegerin/receptor activator of nuclear factor kappa-B/receptor activator of nuclear factor kappa-B ligand and the application of relevant target therapy in oral medicine

Zhou Jing, Zhang Zhao   

  1. Department of Prosthodontics, Hebei Key Laboratory of Stomatology, Hebei Clinical Research Center for Oral Diseases, School and Hospital of Stomatology, Hebei Medical University, Shijiazhuang 050017, Hebei Province, China

  • Received:2023-05-06 Accepted:2023-06-05 Online:2024-08-18 Published:2023-09-14

  • Contact: Zhang Zhao, MD, Associate chief physician, Department of Prosthodontics, Hebei Key Laboratory of Stomatology, Hebei Clinical Research Center for Oral Diseases, School and Hospital of Stomatology, Hebei Medical University, Shijiazhuang 050017, Hebei Province, China

  • About author:Zhou Jing, Master candidate, Physician, Department of Prosthodontics, Hebei Key Laboratory of Stomatology, Hebei Clinical Research Center for Oral Diseases, School and Hospital of Stomatology, Hebei Medical University, Shijiazhuang 050017, Hebei Province, China

  • Supported by:

    Hebei Provincial Department of Finance Scientific Research Project on Prevention and Treatment of Geriatric Diseases, No. 361029 (to ZZ); 2020 Government-funded Clinical Medicine Excellent Talent Training Project of Hebei Provincial Department of Finance, No. 2020048149-2 (to ZZ); Hebei Provincial Health and Health Commission Medical Science Research Project Program, No. 20190098 (to ZZ)


Abstract: BACKGROUND: Osteoprotegerin (OPG)/receptor activator of nuclear factor-κB (RANK)/receptor activator of nuclear factor-κB ligand (RANKL) are important cytokines for coupling osteoclast and osteoblast differentiation and activation, and are key factors for regulating bone metabolism, which affect the immune system, bone regeneration and remodeling, and are closely related to the physiological and pathological remodeling of the alveolar bone.
OBJECTIVE: To analyze the effects of the OPG/RANK/RANKL signaling pathway on alveolar bone remodeling and the progress in its targeted therapy application in the dental field.
METHODS: We searched relevant articles included in CNKI and PubMed databases with the keywords of “OPG, anti-RANKL antibody, RANKL, periodontitis, orthodontic tooth movement, implant, tooth eruption, periapical lesion, alveolar bone resorption” in Chinese and English, respectively. A total of 63 articles were finally included for review.
RESULTS AND CONCLUSION: Anti-RANKL therapy can treat oral diseases by targeting the inhibition of osteoclast formation and alveolar bone absorption. Local and systemic anti-RANKL therapy can inhibit the progression of periodontitis, peri-implantitis and periapical lesions, and it also plays an important role in preventing orthodontic relapse, strengthening orthodontic anchorage and implant osseointegration. RANKL therapy can treat oral diseases by promoting osteoclast differentiation and alveolar bone absorption. RANKL treatment can accelerate orthodontic tooth movement, shorten the treatment cycle and reduce the incidence of orthodontic complications. Although there are limitations in anti-RANKL therapy, they can be avoided by rational applications, such as excluding local and systemic risk factors before treatment, regular oral maintenance and avoiding traumatic alveolar surgery as much as possible during treatment.

Key words: anti-receptor activator of nuclear factor-κB ligand, osteoprotegerin, anti-receptor activator of nuclear factor-κB ligand antibody, receptor activator of nuclear factor-κB ligand, alveolar bone resorption


分享到:

Publishing Information

Publishing House of Chinese Journal of Tissue Engineering Research


The Official Publication of

Chinese Association of Rehabilitation Medicine

Contact Us

General editorial enquiries:

Email: bwb01@crter.org

Copyright related contact:

Email: crter@crter.org

Commercial Sales contact (Reprints, advertising, etc.):

Email: bwb@crter.org